TLC

Taiwan Liposome Company, Ltd. [TLC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TLC Stock Summary

In the News

04:54 28 Mar 2024 TLC

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks

04:41 28 Mar 2024 TLC

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

TAIPEI, Taiwan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company or TLC (Nasdaq: TLC, TWO: 4152, “the Company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that it has notified Nasdaq that it will apply for the voluntary delisting of its American depositary shares (“ADS”s) from the Nasdaq Global Market.

05:44 28 Mar 2024 TLC

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

03:08 28 Mar 2024 TLC

Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop

Looking for the next AMC, retail investors are on the hunt for the next squeeze. Here are five short squeeze stocks to watch this week.

06:16 28 Mar 2024 TLC

TLC Announces Details of Stock Swap Transactions

TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company's board-approved stock swap transactions with Woods Investment Company, Ltd. (“Woods”) at a press conference held at 4:00pm Taipei time at the Taipei Exchange (TPEx). Details of the stock swap transactions are as follows:

07:01 28 Mar 2024 TLC

TLC Stock Price: 28.69% Increase Explanation

The stock price of TLC (Nasdaq: TLC) increased by 28.69% yesterday. This is why it happened.

04:30 28 Mar 2024 TLC

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.

03:46 28 Mar 2024 TLC

Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?

Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average.

08:42 28 Mar 2024 TLC

TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage. AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus.

06:33 28 Mar 2024 TLC

TLC Stock Price: Over 6% Increase Pre-Market Explanation

The stock price of Taiwan Liposome Company (NASDAQ: TLC) increased by over 6% pre-market. This is why it happened.

TLC Financial details

Company Rating
Neutral
Market Cap
0
Income
-803.16M
Revenue
275.97M
Book val./share
3.59
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
27 Oct 2021
P/E
-8.75
Forward P/E
-
PEG
3.88
P/S
-
P/B
19.65
P/C
-
P/FCF
-
Quick Ratio
3.96
Current Ratio
4.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-19.09
EPS next Y
-
EPS next Q
-
EPS this Y
1.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.52%
Revenue last 5Y
19.59%
Revenue Q/Q
325.8%
EPS Q/Q
-62.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.22%
Inst Trans
1.02%
ROA
-56%
ROE
-170%
ROC
-0.7%
Gross Margin
-
Oper. Margin
-965%
Profit Margin
-965%
Payout
-
Shs Outstand
42.08M
Shs Float
26.09M
-
-
-
-
Target Price
-
52W Range
7-7.09
52W High
0%
52W Low
0%
RSI
-
Rel Volume
0.71
Avg Volume
17.61K
Volume
12.42K
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
0.797218
-
-
Volatility
0%, 0%
Prev Close
0%
Price
7
Change
0%

TLC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2016-12-312017-12-312018-12-312019-12-31 2020-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.511.791.996.382.58
Net income per share
-29.78-31.5-28.75-24.64-24.89
Operating cash flow per share
-21.96-29.52-21.88-23.73-22.15
Free cash flow per share
-22.84-30.44-24.1-25.56-23.02
Cash per share
64.9934.335.5431.2433.99
Book value per share
65.1635.5821.3422.0311.08
Tangible book value per share
65.1635.5821.2121.9721.83
Share holders equity per share
65.1635.5821.3422.0311.08
Interest debt per share
4.314.1713.5216.2617.31
Market cap
5.18B4.78B5.27B5.27B4.92B
Enterprise value
3.5B3.94B4.88B4.76B4.24B
P/E ratio
-6.28-5.47-5.85-6.53-5
Price to sales ratio
124.3296.384.5625.2248.23
POCF ratio
-8.52-5.83-7.68-6.78-5.62
PFCF ratio
-8.19-5.66-6.97-6.3-5.4
P/B Ratio
2.874.847.887.3111.23
PTB ratio
2.874.847.887.3111.23
EV to sales
83.9479.3878.2522.7541.6
Enterprise value over EBITDA
-4.69-4.82-5.78-6.72-4.66
EV to operating cash flow
-5.76-4.81-7.11-6.12-4.85
EV to free cash flow
-5.53-4.67-6.45-5.68-4.66
Earnings yield
-0.16-0.18-0.17-0.15-0.2
Free cash flow yield
-0.12-0.18-0.14-0.16-0.19
Debt to equity
0.060.110.620.711.52
Debt to assets
0.060.090.290.370.38
Net debt to EBITDA
2.261.030.470.730.74
Current ratio
9.855.453.451.974.11
Interest coverage
-284.59-265.43-90.2-33.89-60.12
Income quality
0.740.940.760.960.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.42.722.370.81.43
Research and developement to revenue
17.6816.3813.364.119.49
Intangibles to total assets
00000
Capex to operating cash flow
0.040.030.10.080.04
Capex to revenue
-0.59-0.51-1.12-0.29-0.34
Capex to depreciation
-0.33-0.48-1.47-0.84-0.61
Stock based compensation to revenue
2.411.150.660.130.17
Graham number
208.95158.81117.49110.5178.79
ROIC
-0.44-0.82-0.82-0.61-0.84
Return on tangible assets
-0.39-0.69-0.64-0.58-0.56
Graham Net
54.9125.1612.0911.4512.23
Working capital
1.67B858.82M844.41M538.92M1.08B
Tangible asset value
1.8B987.28M665.17M720.11M862.33M
Net current asset value
1.57B776.62M439.97M431.55M545.84M
Invested capital
0.060.110.620.711.52
Average receivables
26.29M25.4M23.16M19.15M28.05M
Average payables
00000
Average inventory
00000
Days sales outstanding
193.05211.51102.7836.22126.58
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
1.891.733.5510.082.88
Payables turnover
00000
Inventory turnover
00000
ROE
-0.46-0.89-1.35-1.12-2.25
Capex per share
-0.89-0.91-2.23-1.83-0.87

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2020-06-302020-09-302020-12-312021-03-31 2021-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.321.570.290.893.81
Net income per share
-6.56-5.56-6.96-4.78-1.79
Operating cash flow per share
00000
Free cash flow per share
0-0.47000
Cash per share
33.41031.9425.640
Book value per share
25.7617.1910.425.63.59
Tangible book value per share
25.7617.1920.5215.2113.21
Share holders equity per share
25.7617.1910.425.63.59
Interest debt per share
0015.8800
Market cap
6.59B5.4B5.23B7.24B6.99B
Enterprise value
5.36B5.4B4.55B6.16B6.99B
P/E ratio
-6.8-5.78-4.47-8.99-23.13
Price to sales ratio
559.7181.68432.83192.4643.62
POCF ratio
00000
PFCF ratio
0-271.96000
P/B Ratio
6.927.4711.9430.746.29
PTB ratio
6.927.4711.9430.746.29
EV to sales
454.8581.68376.95163.7543.62
Enterprise value over EBITDA
-22.13-24.42-15.58-30.63-92.98
EV to operating cash flow
00000
EV to free cash flow
0-271.96000
Earnings yield
-0.04-0.04-0.06-0.03-0.01
Free cash flow yield
00000
Debt to equity
001.5200
Debt to assets
000.3800
Net debt to EBITDA
5.102.315.370
Current ratio
5.834.064.113.13.01
Interest coverage
00000
Income quality
00000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.350.582.920.830.2
Research and developement to revenue
19.444.1122.785.921.37
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
0-0.3000
Capex to depreciation
0-1.59000
Stock based compensation to revenue
00000
Graham number
61.6646.3740.424.5412.03
ROIC
-0.27-0.34-0.23-0.92-0.61
Return on tangible assets
-0.14-0.16-0.17-0.13-0.06
Graham Net
12.42-18.1711.495.01-18.42
Working capital
1.16B873.11M1.08B795.14M659.03M
Tangible asset value
951.99M722.44M862.33M640.63M555.78M
Net current asset value
630.08M394.89M545.84M304.85M211.68M
Invested capital
001.5200
Average receivables
0017.67M17.67M0
Average payables
00000
Average inventory
00000
Days sales outstanding
00263.2800
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
000.3400
Payables turnover
00000
Inventory turnover
00000
ROE
-0.25-0.32-0.67-0.85-0.5
Capex per share
0-0.47000

TLC Frequently Asked Questions

What is Taiwan Liposome Company, Ltd. stock symbol ?

Taiwan Liposome Company, Ltd. is a TW stock and trading under the symbol TLC

What is Taiwan Liposome Company, Ltd. stock quote today ?

Taiwan Liposome Company, Ltd. stock price is $7 today.

Is Taiwan Liposome Company, Ltd. stock public?

Yes, Taiwan Liposome Company, Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Same Industry
Same Price Range
Similar Market Cap